Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding.
BACKGROUND
Bacterial infections are a frequent complication in patients with cirrhosis and upper gastrointestinal bleeding. Antibiotic prophylaxis seems to decrease the incidence of bacterial infections. Oral antibiotics, active against enteric bacteria, have been commonly used as antibiotic prophylaxis in patients with cirrhosis and upper gastrointestinal bleeding. This is an update of a Cochrane review first published in 2002.


OBJECTIVE
To assess the benefits and harms of antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding.


METHODS
We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index EXPANDED until June 2010. In addition, we handsearched the references of all identified studies.


METHODS
Randomised clinical trials comparing different types of antibiotic prophylaxis with no intervention, placebo, or another antibiotic to prevent bacterial infections in cirrhotic patients with upper gastrointestinal bleeding.


METHODS
Three authors independently assessed trial quality, risk of bias, and extracted data. We contacted study authors for additional information. Association measures were relative risk (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes.


RESULTS
Twelve trials (1241 patients) evaluated antibiotic prophylaxis compared with placebo or no antibiotic prophylaxis. All trials were at risk of bias. Antibiotic prophylaxis compared with no intervention or placebo was associated with beneficial effects on mortality (RR 0.79, 95% CI 0.63 to 0.98), mortality from bacterial infections (RR 0.43, 95% CI 0.19 to 0.97), bacterial infections (RR 0.36, 95% CI 0.27 to 0.49), rebleeding (RR 0.53, 95% CI 0.38 to 0.74), days of hospitalisation (MD -1.91, 95% CI -3.80 to -0.02), bacteraemia (RR 0.25, 95% CI 0.15 to 0.40), pneumonia (RR 0.45, 95% CI 0.27 to 0.75), spontaneous bacterial peritonitis (RR 0.29, 95% CI 0.15 to 0.57), and urinary tract infections (RR 0.23, 95% CI 0.12 to 0.41). No serious adverse events were reported. The trials showed no significant heterogeneity of effects. Another five trials (650 patients) compared different antibiotic regimens. Data could not be combined as each trial used different antibiotic regimen. None of the examined antibiotic regimen was superior to the control regimen regarding mortality or bacterial infections.


CONCLUSIONS
Prophylactic antibiotic use in patients with cirrhosis and upper gastrointestinal bleeding significantly reduced bacterial infections, and seems to have reduced all-cause mortality, bacterial infection mortality, rebleeding events, and hospitalisation length. These benefits were observed independently of the type of antibiotic used; thus, no specific antibiotic can be preferred. Therefore, antibiotic selection should be made considering local conditions such as bacterial resistance profile and treatment cost.
Chavez-Tapia
Norberto C
NC
Medica Sur Clinic & Foundation, Puente de Piedra 150, Mexico City, Mexico, 14050.
Barrientos-Gutierrez
Tonatiuh
T
Tellez-Avila
Felix I
FI
Soares-Weiser
Karla
K
Uribe
Misael
M
D019072:Antibiotic Prophylaxis; D001424:Bacterial Infections / Q000401:mortality / Q000517:prevention & control*; D006471:Gastrointestinal Hemorrhage / Q000150:complications* / Q000401:mortality; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications* / Q000401:mortality; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic
J Clin Epidemiol. 2008 Jan;61(1):64-75
18083463
J Chemother. 1989 Aug;1(4):261-5
2681559
Clin Gastroenterol Hepatol. 2009 Dec;7(12):1347-54
19699816
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Acta Gastroenterol Belg. 1992 Jul-Aug;55(4):333-40
1462745
Ann Intern Med. 2001 Dec 4;135(11):982-9
11730399
Lancet. 1998 Aug 22;352(9128):609-13
9746022
Gastroenterology. 2006 Oct;131(4):1049-56; quiz 1285
17030175
Nat Rev Gastroenterol Hepatol. 2009 Oct;6(10):573-82
19724251
Hepatogastroenterology. 2005 Sep-Oct;52(65):1488-90
16201103
J Hepatol. 1993 Jul;18(3):290-4
8228122
Hepatology. 2002 Jan;35(1):140-8
11786970
J Korean Med Sci. 2006 Oct;21(5):883-90
17043424
Hepatology. 1997 Mar;25(3):532-6
9049193
Hepatology. 1996 Oct;24(4):802-6
8855179
Gastrointest Endosc. 1994 Nov-Dec;40(6):680-4
7859964
Curr Med Chem. 2007;14(28):2954-8
18220731
Hepatology. 1999 Apr;29(4):1064-9
10094947
Cochrane Database Syst Rev. 2002;(2):CD002907
12076458
BMJ. 2001 Jul 7;323(7303):42-6
11440947
BMJ. 2003 Jan 25;326(7382):219
12543843
Int J Technol Assess Health Care. 2003 Fall;19(4):591-603
15095765
Hepatology. 2007 Sep;46(3):922-38
17879356
Hepatology. 1994 Jul;20(1 Pt 1):34-8
8020902
Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):72-3
19092789
Gastroenterology. 1992 Oct;103(4):1267-72
1397884
Hepatobiliary Pancreat Dis Int. 2002 Aug;1(3):416-9
14607718
Hepatology. 2004 Mar;39(3):746-53
14999693
Am J Gastroenterol. 1998 Jun;93(6):962-6
9647029
Hepatology. 1990 Oct;12(4 Pt 1):716-24
2210673
Hepatogastroenterology. 1999 Mar-Apr;46(26):1126-30
10370679
JAMA. 1995 Feb 1;273(5):408-12
7823387
Hepatogastroenterology. 2004 Mar-Apr;51(56):541-6
15086198
Am J Gastroenterol. 1998 Dec;93(12):2457-62
9860409
Hepatology. 1999 Jun;29(6):1655-61
10347104
Can J Gastroenterol. 2005 Oct;19(10):607-11
16247523
Taehan Kan Hakhoe Chi. 2002 Sep;8(3):288-96
12499786
J Hepatol. 2008;48 Suppl 1:S68-92
18304681
Hepatology. 1985 May-Jun;5(3):463-7
3873389
J Clin Epidemiol. 2008 Aug;61(8):763-9
18411040
BMJ. 2008 Mar 15;336(7644):601-5
18316340
Zhonghua Yi Xue Za Zhi (Taipei). 2002 Aug;65(8):365-71
12455806
Int J Epidemiol. 2009 Feb;38(1):276-86
18824467
Am J Gastroenterol. 2009 Jul;104(7):1802-29
19455106
N Engl J Med. 1988 Oct 13;319(15):983-9
3262200
Eur J Gastroenterol Hepatol. 2005 Oct;17(10):1105-10
16148557
Hepatology. 1998 May;27(5):1207-12
9581672